Neurocrine Biosciences (NBIX) Cash from Investing Activities (QoQ) (2010 - 2026)
Neurocrine Biosciences (NBIX) Cash from Investing Activities (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -856.90% |
| Dec 31, 2025 | 73.11% |
| Sep 30, 2025 | -578.28% |
| Jun 30, 2025 | -304.23% |
| Mar 31, 2025 | 120.79% |
| Dec 31, 2024 | -376.52% |
| Sep 30, 2024 | 187.59% |
| Jun 30, 2024 | 48.73% |
| Mar 31, 2024 | 72.75% |
| Dec 31, 2023 | -107.40% |
| Sep 30, 2023 | 22.72% |
| Jun 30, 2023 | -199.05% |
| Mar 31, 2023 | 63.58% |
| Dec 31, 2022 | -88.58% |
| Sep 30, 2022 | -295.22% |
| Jun 30, 2022 | 199.37% |
| Mar 31, 2022 | -233.33% |
| Dec 31, 2021 | 118.78% |
| Sep 30, 2021 | -38.99% |
| Jun 30, 2021 | -243.90% |